Diosgenin and Its Analogs: Potential Protective Agents Against Atherosclerosis

Dan Wang,Xiaolong Wang

DOI: https://doi.org/10.2147/DDDT.S368836

2022-07-18

Abstract:Dan Wang, 1– 3 Xiaolong Wang 1– 3 1 Cardiovascular Research Institute of Traditional Chinese Medicine, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China; 2 Cardiovascular Department of Traditional Chinese Medicine, Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Shanghai, People's Republic of China; 3 Shuguang Hospital Affiliated to Shanghai University of Traditional Chinese Medicine, Branch of National Clinical Research Center for Chinese Medicine Cardiology, Shanghai, People's Republic of China Correspondence: Xiaolong Wang, Tel +86 13501991450, Fax +86 21 51322445, Email Atherosclerosis is a chronic inflammatory disease of the artery wall associated with lipid metabolism imbalance and maladaptive immune response, which mediates most cardiovascular events. First-line drugs such as statins and antiplatelet drug aspirin have shown good effects against atherosclerosis but may lead to certain side effects. Thus, the development of new, safer, and less toxic agents for atherosclerosis is urgently needed. Diosgenin and its analogs have gained importance for their efficacy against life-threatening diseases, including cardiovascular, endocrine, nervous system diseases, and cancer. Diosgenin and its analogs are widely found in the rhizomes of Dioscore, Solanum , and other species and share similar chemical structures and pharmacological effects. Recent data suggested diosgenin plays an anti-atherosclerosis role through its anti-inflammatory, antioxidant, plasma cholesterol-lowering, anti-proliferation, and anti-thrombotic effects. However, a review of the effects of diosgenin and its natural structure analogs on AS is still lacking. This review summarizes the effects of diosgenin and its analogs on vascular endothelial dysfunction, vascular smooth muscle cell (VSMC) proliferation, migration and calcification, lipid metabolism, and inflammation, and provides a new overview of its anti-atherosclerosis mechanism. Besides, the structures, sources, safety, pharmacokinetic characteristics, and biological availability are introduced to reveal the limitations and challenges of current studies, hoping to provide a theoretical basis for the clinical application of diosgenin and its analogs and provide a new idea for developing new agents for atherosclerosis. Keywords: atherosclerosis, diosgenin, dioscin, analogs Cardiovascular diseases are the leading cause of death worldwide. According to the World Health Organization, about 17.9 million people die from cardiovascular disease each year, 1 among which atherosclerosis is responsible for the majority of cardiovascular events. Atherosclerosis is a chronic inflammatory disease of the artery wall. It usually appears in the subcutaneous space of medium to large arteries and is associated with lipid metabolism imbalance and maladaptive immune responses. 2 In the early stage of the disease, various pathogenic factors lead to damage of the intima, which further increases the infiltration of inflammatory cells and lipids, and accelerates the formation of foam cells. In the later stage, plaque calcification and rupture occur, leading to the formation of thrombosis and, in turn, ischemic injury syndromes of vital organs, such as myocardial infarction, unstable angina (ischemic heartache), stroke, and other complications. 3 Lowering blood lipids, controlling blood pressure, dilating blood vessels, preventing platelet aggregation from preventing thrombotic complications, etc., are some of the treatment methods for atherosclerosis. Although these therapies alleviate the occurrence and progression of atherosclerosis, they do not target the inflammatory mechanisms responsible for the progression of atherosclerosis. Also, first-line drugs such as statins and antiplatelet drug aspirin in the secondary prevention of ACS have been associated with some adverse reactions such as myitis and myalgia (for statins), 4 gastrointestinal bleeding, ulcers, and increased drug resistance (for antiplatelet drug aspirin). 5,6 Thus, the development of new, safer, and less toxic agents for atherosclerosis is urgently required. At present, phytochemicals have been attracting increasing attention due to their low toxicity and high yield. Diosgenin and its analogs are important natural steroidal saponins used as active ingredients of dioscin tablets, Di'ao Xin Xue Kang capsules, Dunye Guan Xin Ning, and other medicines which have been used in China for more than 20 years to treat coronary heart disease and other cardiovascular diseases. 7–9 Many experimental studies and some clinical trials have demonstrated that diosgenin and its analogs have anti-inflammatory, antioxidant, plasma -Abstract Truncated-